Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice

por Prijovich, Z M, Chen, B-M, Leu, Y-L, Chern, J-W, Roffler, S R
Publicado 2002

A novel germline mutation of PTEN associated with brain tumours of multiple lineages

por Staal, F J T, van der Luijt, R B, Baert, M R M, van Drunen, J, van Bakel, H, Peters, E, de Valk, I, van Amstel, H K P, Taphoorn, M J B, Jansen, G H, van Veelen, C W M, Burgering, B, Staal, G E J
Publicado 2002

The unrecognised cost of cancer patients' unrelieved symptoms:a nationwide follow-up of their surviving partners

por Valdimarsdóttir, U, Helgason, ÁR, Fürst, C-J, Adolfsson, J, Steineck, G
Publicado 2002

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

por Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, M R, Ward, T, Dive, C
Publicado 2012

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation

por Wilkins, Anna, Gusterson, Barry, Tovey, Holly, Griffin, Clare, Stuttle, Christine, Daley, Frances, Corbishley, Catherine M., Dearnaley, David, Hall, Emma, Somaiah, Navita
Publicado 2023

Cancer incidence among the south Asian and non-south Asian population under 30 years of age in Yorkshire, UK

por van Laar, M, McKinney, P A, Parslow, R C, Glaser, A, Kinsey, S E, Lewis, I J, Picton, S V, Richards, M, Shenton, G, Stark, D, Norman, P, Feltbower, R G
Publicado 2013

Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer

por Wong, C K E, Namdarian, B, Chua, J, Chin, X, Speirs, R, Nguyen, T, Fankhauser, M, Pedersen, J, Costello, A J, Corcoran, N M, Hovens, C M
Publicado 2013

Reply: Comment on 'Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma'

por Kantola, T, Klintrup, K, Väyrynen, J P, Vornanen, J, Bloigu, R, Karhu, T, Herzig, K-H, Näpänkangas, J, Mäkelä, J, Karttunen, T J, Tuomisto, A, Mäkinen, M J
Publicado 2013

Reply: Comment on ‘Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage' –...

por Carlson, L E, Waller, A, Groff, S L, Bultz, B D
Publicado 2013

Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors

por Willemse, P M, Burggraaf, J, Hamdy, N A T, Weijl, N I, Vossen, C Y, van Wulften, L, van Steijn-van Tol, A Q M J, Rosendaal, F R, Osanto, S
Publicado 2013

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer

por Stotz, M, Gerger, A, Eisner, F, Szkandera, J, Loibner, H, Ress, A L, Kornprat, P, AlZoughbi, W, Seggewies, F S, Lackner, C, Stojakovic, T, Samonigg, H, Hoefler, G, Pichler, M
Publicado 2013

DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers

por Suzuki, M, Shigematsu, H, Shames, D S, Sunaga, N, Takahashi, T, Shivapurkar, N, Iizasa, T, Frenkel, E P, Minna, J D, Fujisawa, T, Gazdar, A F
Publicado 2013

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

por Tural, D, Serdengecti, S, Demirelli, F, Öztürk, T, İlvan, S, Turna, H, Özgüroglu, M, Büyükünal, E
Publicado 2014

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'

por Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, C, Muñoz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Tabernero, S, Barbacid, M, Lopez-Rios, F, Hidalgo, M
Publicado 2014

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

por Choughule, A, Sharma, R, Trivedi, V, Thavamani, A, Noronha, V, Joshi, A, Desai, S, Chandrani, P, Sundaram, P, Utture, S, Jambhekar, N, Gupta, S, Aich, J, Prabhash, K, Dutt, A
Publicado 2014

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

por Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Publicado 2014

Modification of N staging systems for penile cancer: a more precise prediction of prognosis

por Li, Z-S, Yao, K, Chen, P, Wang, B, Chen, J-P, Mi, Q-W, Li, Y-H, Liu, Z-W, Qin, Z-K, Zhou, F-J, Han, H
Publicado 2015

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer

por Koti, M, Siu, A, Clément, I, Bidarimath, M, Turashvili, G, Edwards, A, Rahimi, K, Mes-Masson, A-M, Squire, J A
Publicado 2015

Hypermethylation of the 5′ CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis

por Manton, K J, Douglas, M L, Netzel-Arnett, S, Fitzpatrick, D R, Nicol, D L, Boyd, A W, Clements, J A, Antalis, T M
Publicado 2015

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer

por Soh, C-L, McNeil, K, Owczarek, C M, Hardy, M P, Fabri, L J, Pearse, M, Delaine, C A, Forbes, B E
Publicado 2015